These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

55 related items for PubMed ID: 24372207

  • 1. Recent highlights in the synthesis of anti-HCV ribonucleosides.
    Piperno A, Cordaro M, Scala A, Iannazzo D.
    Curr Med Chem; 2014; 21(16):1843-60. PubMed ID: 24372207
    [Abstract] [Full Text] [Related]

  • 2. Base-modified ribonucleosides as potential anti-hepatitis C virus agents.
    Ivanov AV, Smirnova OA, Golubeva NA, Ivanov MA, Tunitskaya VL, Shipitsyn AV, Alexandrova LA.
    Nucleic Acids Symp Ser (Oxf); 2008; (52):619-20. PubMed ID: 18776532
    [Abstract] [Full Text] [Related]

  • 3. Design and synthesis of novel carbocyclic versions of 2'-spirocyclopropyl ribonucleosides as potent anti-HCV agents.
    Oh CH, Kim E, Hong JH.
    Nucleosides Nucleotides Nucleic Acids; 2011 Jun; 30(6):423-39. PubMed ID: 21780908
    [Abstract] [Full Text] [Related]

  • 4. Protease Inhibitors Block Multiple Functions of the NS3/4A Protease-Helicase during the Hepatitis C Virus Life Cycle.
    McGivern DR, Masaki T, Lovell W, Hamlett C, Saalau-Bethell S, Graham B.
    J Virol; 2015 May; 89(10):5362-70. PubMed ID: 25740995
    [Abstract] [Full Text] [Related]

  • 5. Cytostatic and antiviral 6-arylpurine ribonucleosides. Part 7: synthesis and evaluation of 6-substituted purine l-ribonucleosides.
    Hocek M, Silhár P, Shih IH, Mabery E, Mackman R.
    Bioorg Med Chem Lett; 2006 Oct 15; 16(20):5290-3. PubMed ID: 16905315
    [Abstract] [Full Text] [Related]

  • 6. Sensitivity of mitochondrial transcription and resistance of RNA polymerase II dependent nuclear transcription to antiviral ribonucleosides.
    Arnold JJ, Sharma SD, Feng JY, Ray AS, Smidansky ED, Kireeva ML, Cho A, Perry J, Vela JE, Park Y, Xu Y, Tian Y, Babusis D, Barauskus O, Peterson BR, Gnatt A, Kashlev M, Zhong W, Cameron CE.
    PLoS Pathog; 2012 Oct 15; 8(11):e1003030. PubMed ID: 23166498
    [Abstract] [Full Text] [Related]

  • 7. Synthesis of 2'-O,4'-C-alkylene-bridged ribonucleosides and their evaluation as inhibitors of HCV NS5B polymerase.
    Chapron C, Glen R, La Colla M, Mayes BA, McCarville JF, Moore S, Moussa A, Sarkar R, Seifer M, Serra I, Stewart A.
    Bioorg Med Chem Lett; 2014 Jun 15; 24(12):2699-702. PubMed ID: 24815510
    [Abstract] [Full Text] [Related]

  • 8. Synthesis and antiviral evaluation of 2'-C-methyl analogues of 5-alkynyl- and 6-alkylfurano- and pyrrolo[2,3-d]pyrimidine ribonucleosides.
    Januszczyk P, Fogt J, Boryski J, Izawa K, Onishi T, Neyts J, De Clercq E.
    Nucleosides Nucleotides Nucleic Acids; 2009 May 15; 28(5):713-23. PubMed ID: 20183611
    [Abstract] [Full Text] [Related]

  • 9. Cytostatic 6-arylpurine nucleosides. 6. SAR in anti-HCV and cytostatic activity of extended series of 6-hetarylpurine ribonucleosides.
    Hocek M, Naus P, Pohl R, Votruba I, Furman PA, Tharnish PM, Otto MJ.
    J Med Chem; 2005 Sep 08; 48(18):5869-73. PubMed ID: 16134952
    [Abstract] [Full Text] [Related]

  • 10. Synthesis of new 2'-beta-C-methyl related triciribine analogues as anti-HCV agents.
    Smith KL, Lai VC, Prigaro BJ, Ding Y, Gunic E, Girardet JL, Zhong W, Hong Z, Lang S, An H.
    Bioorg Med Chem Lett; 2004 Jul 05; 14(13):3517-20. PubMed ID: 15177464
    [Abstract] [Full Text] [Related]

  • 11. Synthesis of 7-trifluoromethyl-7-deazapurine ribonucleoside analogs and their monophosphate prodrugs.
    Cho JH, Bassit LC, Amblard F, Schinazi RF.
    Nucleosides Nucleotides Nucleic Acids; 2020 Jul 05; 39(5):671-687. PubMed ID: 31588837
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Future treatment of chronic hepatitis C with direct acting antivirals: is resistance important?
    Halfon P, Sarrazin C.
    Liver Int; 2012 Feb 05; 32 Suppl 1():79-87. PubMed ID: 22212577
    [Abstract] [Full Text] [Related]

  • 14. New HCV therapies on the horizon.
    Vermehren J, Sarrazin C.
    Clin Microbiol Infect; 2011 Feb 05; 17(2):122-34. PubMed ID: 21087349
    [Abstract] [Full Text] [Related]

  • 15. New opportunities in anti-hepatitis C virus drug discovery: targeting NS4B.
    Rai R, Deval J.
    Antiviral Res; 2011 May 05; 90(2):93-101. PubMed ID: 21295075
    [Abstract] [Full Text] [Related]

  • 16. Novel therapies for hepatitis C: insights from the structure of the virus.
    Fusco DN, Chung RT.
    Annu Rev Med; 2012 May 05; 63():373-87. PubMed ID: 21942423
    [Abstract] [Full Text] [Related]

  • 17. New antiviral therapies in the management of HCV infection.
    Farnik H, Zeuzem S.
    Antivir Ther; 2012 May 05; 17(5):771-83. PubMed ID: 22626842
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Macrocyclic Hepatitis C Virus NS3/4A Protease Inhibitors: An Overview of Medicinal Chemistry.
    Pillaiyar T, Namasivayam V, Manickam M.
    Curr Med Chem; 2016 May 05; 23(29):3404-3447. PubMed ID: 27160539
    [Abstract] [Full Text] [Related]

  • 20. [RESISTANCE OF HCV TO NEW DIRECT ACTING ANTIVIRALS].
    Gozlan Y, Mendelson E, Ben-Ari Z, Mor O.
    Harefuah; 2015 Nov 05; 154(11):684-7, 743. PubMed ID: 26821497
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 3.